Key result
Influenza vaccines and emerging neuraminidase inhibitors provide effective prophylaxis and therapy, addressing the limitations of older antiviral drugs and patchy vaccine coverage.
Population
General population and patients at high risk of complications and mortality, including the elderly and those…
Design
Review
Authors
Loading...
Supports consideration in high-risk cardiac patients; leaves open dedicated cardiovascular outcome trials.
Highlights the need for new influenza vaccines and the promise of neuraminidase inhibitors to overcome limitations of older antiviral drugs.
Stephenson et al. (2001) conducted a review in Influenza. Vaccination and antiviral treatment was evaluated. Influenza vaccines and emerging neuraminidase inhibitors provide effective prophylaxis and therapy, addressing the limitations of older antiviral drugs and patchy vaccine coverage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: